Investigational drug · Phase 3
QL1604
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small-cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "QL1604"
First trial start
2025
Feb 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QL1604", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small-cell Lung Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "QL1604" as an intervention, largest first.
- a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06789796 · 636 participants (planned) · Start Feb 2025 · Primary completion Mar 2028
Drug: Iparomlimab and Tuvonralimab (QL1706); placebo for QL1604 and 2 more · For: Small-cell Lung Cancer
- A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.Pivotal-lookingStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT04435652 · 492 participants (planned) · Start Jul 1, 2020 · Primary completion Apr 30, 2022
Drug: QL1604; Nab-paclitaxel and 1 more · For: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Shanghai, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT04326829 · 86 participants (planned) · Start Jul 8, 2020 · Primary completion Dec 2022
Drug: QL1604 · For: Advanced Malignant Tumor
Sites: Shanghai, China; Chengdu, China
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular CarcinomaStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT05603039 · 80 participants (planned) · Start Jul 1, 2021 · Primary completion Dec 30, 2023
Drug: QL1706; QL1604 and 1 more · For: Advanced Liver Cancer
Sites: Chengdu, China
- A Phase I Study of QL1604 for Advanced Solid TumorsStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT05801094 · 71 participants · Start Jul 20, 2020 · Primary completion Apr 15, 2023
Drug: QL1604 · For: Advanced Solid Tumor
Sites: Nanchang, China; Shanghai, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT05649761 · 61 participants (planned) · Start May 29, 2019 · Primary completion Jul 10, 2020
Drug: QL1604 injection · For: Advanced Solid Tumors
Sites: Hangzhou, China
- QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical CancerPivotal-lookingTerminated
Qilu Pharmaceutical Co., Ltd.Industry
NCT04864782 · 46 participants · Start Sep 23, 2020 · Primary completion Sep 30, 2022
Drug: QL1604; Paclitaxel injection and 1 more · For: Cervical Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Bi F, Dong J, Jin C, et al. · J Hematol Oncol 2024
- Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study.
Xiong J, Ouyang W, Yang M, et al. · Adv Ther 2024
- QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
Fang C, Zhou Y, Feng Y, et al. · J Gynecol Oncol 2024
- QL1604 combined with bevacizumab as an innovative first-line treatment for HCC patient with extensive metastasis who showed remarkable effect: a case report.
Wan Y, Tan K, Zhu H · Front Pharmacol 2024
- A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z, Xu Y, Hong W, et al. · Front Immunol 2023
Also in development for Small-cell Lung Cancer
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- ZL-1310Phase 33 trials
Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- IparomlimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- TuvonralimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.